GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » E10

LEXX (Lexaria Bioscience) E10 : $-1.45 (As of Aug. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Lexaria Bioscience's adjusted earnings per share data for the three months ended in Aug. 2024 was $-0.150. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.45 for the trailing ten years ended in Aug. 2024.

During the past 3 years, the average E10 Growth Rate was -1.40% per year. During the past 5 years, the average E10 Growth Rate was -1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Lexaria Bioscience was 18.10% per year. The lowest was -4.10% per year. And the median was -0.80% per year.

As of today (2024-12-12), Lexaria Bioscience's current stock price is $2.26. Lexaria Bioscience's E10 for the quarter that ended in Aug. 2024 was $-1.45. Lexaria Bioscience's Shiller PE Ratio of today is .


Lexaria Bioscience E10 Historical Data

The historical data trend for Lexaria Bioscience's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience E10 Chart

Lexaria Bioscience Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.41 -1.39 -1.52 -1.59 -1.45

Lexaria Bioscience Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -1.57 -1.54 -1.51 -1.45

Competitive Comparison of Lexaria Bioscience's E10

For the Biotechnology subindustry, Lexaria Bioscience's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's Shiller PE Ratio falls into.



Lexaria Bioscience E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lexaria Bioscience's adjusted earnings per share data for the three months ended in Aug. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Aug. 2024 (Change)*Current CPI (Aug. 2024)
=-0.15/127.8378*127.8378
=-0.150

Current CPI (Aug. 2024) = 127.8378.

Lexaria Bioscience Quarterly Data

per share eps CPI Adj_EPS
201411 -0.273 99.078 -0.352
201502 -0.273 99.078 -0.352
201505 -0.273 100.263 -0.348
201508 -0.109 100.579 -0.139
201511 -0.300 100.421 -0.382
201602 -0.300 100.421 -0.382
201605 -0.300 101.765 -0.377
201608 -0.300 101.686 -0.377
201611 -0.300 101.607 -0.377
201702 -0.300 102.476 -0.374
201705 -0.300 103.108 -0.372
201708 -0.300 103.108 -0.372
201711 -0.300 103.740 -0.370
201802 -0.600 104.688 -0.733
201805 -1.500 105.399 -1.819
201808 -0.300 106.031 -0.362
201811 -0.300 105.478 -0.364
201902 -0.300 106.268 -0.361
201905 -0.300 107.927 -0.355
201908 -0.300 108.085 -0.355
201911 -0.330 107.769 -0.391
202002 -0.380 108.559 -0.447
202005 -0.500 107.532 -0.594
202008 -0.240 108.243 -0.283
202011 -0.240 108.796 -0.282
202102 0.090 109.745 0.105
202105 -0.500 111.404 -0.574
202108 -0.240 112.668 -0.272
202111 -0.350 113.932 -0.393
202202 -0.250 115.986 -0.276
202205 -0.410 120.016 -0.437
202208 -0.240 120.569 -0.254
202211 -0.300 121.675 -0.315
202302 -0.220 122.070 -0.230
202305 -0.370 124.045 -0.381
202308 -0.120 125.389 -0.122
202311 -0.130 125.468 -0.132
202402 -0.060 125.468 -0.061
202405 -0.130 127.601 -0.130
202408 -0.150 127.838 -0.150

Add all the adjusted EPS together and divide 10 will get our e10.


Lexaria Bioscience  (NAS:LEXX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Lexaria Bioscience E10 Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience Business Description

Traded in Other Exchanges
N/A
Address
740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Executives
Catherine C. Turkel director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Vanessa Carle officer: Secretary 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Gregory Downey officer: Chief Financial Officer 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka director, 10 percent owner, officer: CEO 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Reese Albert L Jr director
Brian W. Quigley director 100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie director 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger officer: CFO 8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty director, 10 percent owner 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar director, officer: CFO 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter director 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford director 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke officer: Sr. VP, Business Development 38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini director, 10 percent owner 11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan director, officer: Vice President - Corp Develop SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6